Showing 181 - 200 results of 240 for search '"hepatitis B virus"', query time: 0.09s Refine Results
  1. 181

    The type of infections and the use of antibiotics among patients with rheumatoid arthritis: A review by Asma D. Alshammari, Mona Matar Aldhafeeri, Amal M. Aldhafeeri, Maram Asaad Alanzi, Maha Bandar Almutairi, Jawaher Abdullah Alrasheedi, Thikra Adel Alsurur, Aeshah Dhahawi Alshammri

    Published 2025-01-01
    “…In all patients with rheumatoid arthritis, it is necessary to conduct initial screenings for hepatitis B virus and tuberculosis. Additionally, it is important to administer vaccinations for specific pathogens (such as pneumococcal, herpes zoster, and influenza) before and during treatment. …”
    Get full text
    Article
  2. 182

    Machine Learning-based Prediction of HBV-related Hepatocellular Carcinoma and Detection of Key Candidate Biomarkers by Zeynep KUCUKAKCALI, Sami AKBULUT, Cemil COLAK

    Published 2022-09-01
    “…Objective: This study aimed to classify open-access gene expression data of patients with hepatitis B virus-related hepatocellular carcinoma (HBV + HCC) and chronic HBV without HCC (HBV alone) using the XGBoost method, one of the machine learning methods, and reveal important genes that may cause HCC. …”
    Get full text
    Article
  3. 183
  4. 184

    Autoimmune and Neoplastic Thyroid Diseases Associated with Hepatitis C Chronic Infection by Poupak Fallahi, Silvia Martina Ferrari, Ugo Politti, Dilia Giuggioli, Clodoveo Ferri, Alessandro Antonelli

    Published 2014-01-01
    “…Frequently, patients with hepatitis C virus (HCV) chronic infection have high levels of serum anti-thyroperoxidase and/or anti-thyroglobulin autoantibodies, ultrasonographic signs of chronic autoimmune thyroiditis, and subclinical hypothyroidism, in female gender versus healthy controls, or hepatitis B virus infected patients. In patients with “HCV-associated mixed cryoglobulinemia” (MC + HCV), a higher prevalence of thyroid autoimmune disorders was shown not only compared to controls, but also versus HCV patients without cryoglobulinemia. …”
    Get full text
    Article
  5. 185

    HIV/AIDS and HBV co-infection with optimal control strategies and cost-effectiveness analyses using integer order model by Shewafera Wondimagegnhu Teklu, Abushet Hayalu Workie

    Published 2025-02-01
    “…Abstract Hepatitis B virus (HBV) and HIV/AIDS co-infection is a common infectious disease that has been spreading through different nations in the world. …”
    Get full text
    Article
  6. 186

    Incidence of HBV Reactivation in Psoriasis Patients Undergoing Cytokine Inhibitor Therapy: A Single-Center Study and Systematic Review with a Meta-Analysis by Meng Hsuan Kuo, Ping-Hung Ko, Sz-Tsan Wang, Chih-Wei Tseng

    Published 2024-12-01
    “…Background: Psoriasis patients who are seropositive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) face an elevated risk of hepatitis B virus reactivation (HBVr) when treated with cytokine inhibitors. …”
    Get full text
    Article
  7. 187

    Prevalence and trends of transfusion transmissible infections among blood donors in Basra, Iraq by Khairallah A S Mohammed, Maha M Hameed, Abdullah H Mousa, Amar T Saleh

    Published 2023-07-01
    “…A total of 197 898 samples were collected and screened for hepatitis B surface antigen (HBsAg), anti-hepatitis B core (HBc), anti-hepatitis C virus (HCV) and syphilis immunologically.Results The prevalence rates of seropositive of viral hepatitis for the year 2019, 2020, 2021 were as following: hepatitis B virus (HBV) rates 1.54%, 1.45% and 1.14% with significant declined trend by 26%; anti-HCV rates were 0.14, 0.12 and 0.11% with significant declined trend by 21.4%; and the syphilis rates were 0.38, 0.47, 0.36 with marked declined trend 5.3%, respectively.Of those donors showed HBV positive, 2503 (1.26%) had positive anti-HBc results, while only 173 (0.0874) showed positive test results for both anti-HBc and HBsAg.Conclusion Prevalence rates of viral hepatitis and syphilis showed a steady decline between 2019 and 2021, and these rates were much lower in Basra than in other parts of Iraq and neighbouring countries. …”
    Get full text
    Article
  8. 188

    HLA I immunopeptidome of synthetic long peptide pulsed human dendritic cells for therapeutic vaccine design by Amy L. Kessler, Roel F. A. Pieterman, Wouter A. S. Doff, Karel Bezstarosti, Rachid Bouzid, Kim Klarenaar, Diahann T. S. L. Jansen, Robbie J. Luijten, Jeroen A. A. Demmers, Sonja I. Buschow

    Published 2025-01-01
    “…Here, we generated a unique, high-quality immunopeptidome dataset of human DCs pulsed with 12 hepatitis B virus (HBV)-based SLPs combined with either a TLR1/2 (Amplivant®) or TLR3 (PolyI:C) ligand. …”
    Get full text
    Article
  9. 189

    Hepatitis B Vaccination Induced TNF-α- and IL-2-Producing T Cell Responses in HIV− Healthy Individuals Higher than in HIV+ Individuals Who Received the Same Vaccination Regimen by Kriangkrai Chawansuntati, Kanokporn Chaiklang, Romanee Chaiwarith, Jutarat Praparattanapan, Khuanchai Supparatpinyo, Jiraprapa Wipasa

    Published 2018-01-01
    “…We investigated cytokine production and expression of degranulation marker CD107a after different strategies of hepatitis B virus (HBV) vaccination in human immunodeficiency virus-infected individuals, which were three doses of 20 μg (standard dose group), four doses of 20 μg (four doses group), or four doses of 40 μg (four double doses group), compared to standard dose vaccination in healthy controls. …”
    Get full text
    Article
  10. 190

    Epidemiology of Hepatocellular Carcinoma by Mimi C Yu, Jian-Min Yuan, Sugantha Govindarajan, Ronald K Ross

    Published 2000-01-01
    “…Chronic infection by the hepatitis B virus (HBV) is by far the most important risk factor for HCC in humans. …”
    Get full text
    Article
  11. 191

    Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases—meta‐analytic assessment by Kazuo Tarao, Akito Nozaki, Takaaki Ikeda, Akira Sato, Hirokazu Komatsu, Tatsuji Komatsu, Masataka Taguri, Katsuaki Tanaka

    Published 2019-03-01
    “…Results The annual incidence (%) of HCC in the non‐cirrhotic stage and cirrhotic stage, and the ratio of HCC incidence in the cirrhotic stage/non‐cirrhotic stage were as follows. (a) hepatitis B virus liver disease: 0.37%→3.23% (8.73‐fold), (b) hepatitis C virus liver diseases: 0.68%→4.81% (7.07‐fold), (c) primary biliary cholangitis (0.26%→1.79%, 6.88‐fold), (d) autoimmune hepatitis (0.19%→0.53%, 2.79‐fold), and (e) NASH (0.03%→1.35%, 45.00‐fold). …”
    Get full text
    Article
  12. 192

    Risk of Hepatocellular Carcinoma Remains High in Patients with HBV-Related Decompensated Cirrhosis and Long-Term Antiviral Therapy by Dong-Mei Zhu, Jing Xie, Chun-Yan Ye, Mei-Yun Qian, Yuan Xue

    Published 2020-01-01
    “…This study aimed to evaluate the risk factors of HCC development in patients with hepatitis B virus (HBV)-related DC and who underwent long-term antiviral therapy. …”
    Get full text
    Article
  13. 193

    Analysis of the Serum Bile Acid Composition for Differential Diagnosis in Patients with Liver Disease by Tomonori Sugita, Katsushi Amano, Masanori Nakano, Noriko Masubuchi, Masahiro Sugihara, Tomokazu Matsuura

    Published 2015-01-01
    “…A total of 150 subjects, including patients with hepatitis C virus (HCV) (n=44), hepatitis B virus (HBV) (n=23), alcoholic liver disease (ALD) (n=21), biliary tract disease (n=20), nonalcoholic fatty liver disease (NAFLD) (n=13), and other liver diseases (n=29), were recruited. …”
    Get full text
    Article
  14. 194

    A Reverse Design Method for Convective PCR Chips Featuring Precise Control of Steady-State Flow Fields by Chenfei Li, Yaping Xie, Haochen Yong, Xin Zhao, Xingxing Ke, Zhigang Wu

    Published 2025-01-01
    “…Ultimately, a reaction chamber was designed based on the actual amplification needs of 2019-nCoV and hepatitis B virus, and successful amplification was achieved using a self-developed temperature control platform.…”
    Get full text
    Article
  15. 195

    Risk of Cirrhosis in Patients with Non-alcoholic Fatty Liver Disease and Previous Viral Hepatitis B by S. N. Batskikh, E. V. Vinnitskaya, E. S. Sbikina, Zh. V. Borunova, A. S. Dorofeev, Yu. G. Sandler

    Published 2020-09-01
    “…To confirm previous and occult hepatitis B virus (HBV) infection, blood of all participants was examined for anti-HBc (IgG) and HBV DNA. …”
    Get full text
    Article
  16. 196

    Expression of Interferon Effector Gene SART1 Correlates with Interferon Treatment Response against Hepatitis B Infection by Yong Li, Chuanlong Zhu, Faxi Wang, Tiantian Zhu, Jun Li, Shufeng Liu, Fei Xiao

    Published 2016-01-01
    “…In this study, we investigated the role of SART1 in antiviral activity of IFN-α against hepatitis B virus (HBV) using blood and liver biopsy samples from chronic hepatitis B patients treated with pegylated IFN-α and HepG2 cells transfected with cloned HBV DNA. …”
    Get full text
    Article
  17. 197

    Acute hepatitis of non-specified etiology by Ye. V. Tsyganova, O. O. Znoyko, N. D. Yushchuk, K. R. Dudina, M. G. Isagulyants, N. V. Petrakova, T. V. Petrova, M. I. Mikhaylov

    Published 2011-02-01
    “…Investigation of patients with acute hepatitis of non-specified etiology included clinical, epidemiologic, routine laboratory, serological methods; molecular biological method (RNA of hepatitis A, C, Е, G viruses; DNA of hepatitis B virus, TTV, CMV, EBV, HHV of 1, 2, 6 and 8 types, PV B-19, NV-f – qualitative analysis); method of immunofluorescence (assessment of antimitochondrial and antinuclear antibodies); immunologic methods (laboratory diagnostic methods) – independent assessment of specific antibodies for individual HCV antigens spectrum, including structural and unstructural proteins and compound peptides, representing the whole HCV polyprotein (overall 38 antigens: 34 HCV antigens and 4 control antigens) in blood serum by EIA method; investigation of Т-cellular immune response to HCV antigens by blast-cell lymphocytes transformation method under stimulation by HCV antigens with quantitative evaluation of cytokine secretion; instrumental method – ultrasound investigation of abdominal organs.Conclusions. …”
    Get full text
    Article
  18. 198

    Late Onset of Antiretroviral Therapy in Adults Living with HIV in an Urban Area in Brazil: Prevalence and Risk Factors by Priscila Ribeiro Guimarães Pacheco, Ana Laura Sene Amâncio Zara, Luiz Carlos Silva e Souza, Marília Dalva Turchi

    Published 2019-01-01
    “…After logistic regression, factors shown to be associated with late initiation of ARV were low education level, sexual orientation, high baseline viral load, place of residence outside metropolitan area, and concomitant infection with hepatitis B virus. Conclusion. These results revealed the need to increase early treatment of HIV infection, focusing especially on groups of people who are more socially vulnerable or have lower self-perceived risk.…”
    Get full text
    Article
  19. 199

    Analysis of Extrahepatic Multiple Primary Malignancies in Patients with Hepatocellular Carcinoma according to Viral Infection Status by Keita Kai, Atsushi Miyoshi, Kenji Kitahara, Masanori Masuda, Yukari Takase, Kohji Miyazaki, Hirokazu Noshiro, Osamu Tokunaga

    Published 2012-01-01
    “…However, its correlation with viral infection, such as hepatitis B virus (HBV) or hepatitis C virus (HCV), has not been examined. …”
    Get full text
    Article
  20. 200

    The Possible Role of TLR2 in Chronic Hepatitis B Patients with Precore Mutation by Malihe Moradzadeh, Sirous Tayebi, Hossein Poustchi, Kourosh Sayehmiri, Parisa Shahnazari, Elnaz Naderi, Ghodratollah Montazeri, Ashraf Mohamadkhani

    Published 2013-01-01
    “…In this study, the frequency of precore mutations of the hepatitis B virus (HBV) and serum TLR2 were evaluated in CHB patients. …”
    Get full text
    Article